Bleomycin (sulfate) [9041-93-4]
Referentie HY-17565-10mg
Formaat : 10mg
Merk : MedChemExpress
Bleomycin sulfate is a DNA synthesis inhibitor. Bleomycin hydrochloride is a DNA damaging agent. Bleomycin sulfate is an antitumor antibiotic.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
Bleomycin sulfate Chemical Structure
CAS No. : 9041-93-4
This product is a controlled substance and not for sale in your territory.
Based on 81 publication(s) in Google Scholar
Other Forms of Bleomycin sulfate:
- Bleomycin hydrochloride In-stock
- Bleomycin Obtenir un devis
Description |
Bleomycin sulfate is a DNA synthesis inhibitor. Bleomycin hydrochloride is a DNA damaging agent. Bleomycin sulfate is an antitumor antibiotic[1]. |
IC50 & Target |
DNA/RNA Synthesis[1] |
||||||
---|---|---|---|---|---|---|---|---|---|
In Vitro |
Bleomycin (BLM) sulfate is chosen as the best-studied micronucleus (MN) inducers in human lymphocytes with different mechanisms of genotoxicity. The most frequent Bleomycin-induced DNA lesions are single and double strand breaks and single apuinic/apyrimidinic sites. At the same time Bleomycin is true radiomimetic compound, resembling almost completely the genetic effect of ionizing radiation[1]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||
In Vivo |
Bleomycin (BLM) sulfate is chosen as the best-studied micronucleus (MN) inducers in human lymphocytes with different mechanisms of genotoxicity. The most frequent Bleomycin-induced DNA lesions are single and double strand breaks and single apuinic/apyrimidinic sites. At the same time Bleomycin is true radiomimetic compound, resembling almost completely the genetic effect of ionizing radiation[1]. Induction of Pulmonary Fibrosis[7]
Background
Bleomycin sulfate can lead to lung patchy parenchymal inflammation, epithelial cell injury with reactive hyperplasia, epithelial-mesenchymal transition, activation and differentiation of fibroblasts to myofibroblasts, and basement membrane and alveolar epithelium injures. The experimental use of Bleomycin sulfate is to induce pulmonary fibrosis animal models.
Specific Modeling Methods
Mice: C57BL/6 • 12-week-old Administration: 3-5 mg/kg • intratracheal administration • sprays on day one
Note
The mice were housed in separate stainless-steel cages (six mice per cage) in a temperature-controlled environment (20-24°C) on 12 h light-dark cycles with unrestricted access to food and water.
Modeling Indicators
Body quality changes: The appetite activity is reduced, with the fur less shiny, the spirits being lethargic, and the bodyweight decreasing. Showed shortness of breath, coughing, and noisy.
Lung changes: Increased fibrotic consolidations, non-aerated lung area, and high-density lung area. Pulmonary function decreased. Molecular changes: Increased indicators: TGF-β1, TNF-α, IL-6, and GM-CSF in bronchoalveolar lavage fluid. Correlated Product(s) Bleomycin hydrochloride (HY-17565A) Opposite Product(s) Neotuberostemonine (HY-N3196) MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
|
||||||||
Essai clinique |
|
||||||||
Masse moléculaire |
1523 (average) |
||||||||
CAS No. |
9041-93-4 |
||||||||
Appearance |
Solid |
||||||||
Color |
White to light yellow |
||||||||
SMILES |
O=C(C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C)N[C@H](C(N[C@H](C)[C@@H](O)[C@H](C)C(N[C@]([C@H](O)C)(19)C(NCCC2=NC(C3=NC(C(N[R])=O)=CS3)=CS2)=O)=O)=O)[C@H](C4=CN=CN4)O[C@H]5[C@H]([C@H]([C@@H]([C@@H](O5)CO)O)O)O[C@]6(19)[C@H]([C@H]([C@@H]([C@H](O6)CO)O)OC(N)=O)O.NC(NCCCC[R])=N.[R]CCC[S+](C)C.O=S(O)(O)=O.[R=].[Bleomycin A2].[R=].[Bleomycin B2] |
||||||||
Structure Classification |
|
||||||||
Initial Source |
Streptomyces verticillus |
||||||||
Livraison | Room temperature in continental US; may vary elsewhere. |
||||||||
Stockage |
4°C, sealed storage, away from moisture *In solvent : -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture) |
||||||||
Solvant et solubilité |
In Vitro:
H2O : 255 mg/mL (Need ultrasonic and warming) DMSO : 41.67 mg/mL (Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol) Concentration (start) × Volume (start) = Concentration (final) × Volume (final) This equation is commonly abbreviated as: C1V1 = C2V2 In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
For the following dissolution methods, please prepare the working solution directly.
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
Dosage mg/kgAnimal weight Dosing volume Number of animals Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration:
mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).
|
||||||||
Pureté et documentation | |||||||||
Références |
|
Bleomycin sulfate Related Classifications
- Induced Disease Models Products
- Respiratory System Disease Models
- Cell Cycle/DNA Damage Anti-infection
- DNA/RNA Synthesis Antibiotic